[O:1]1[CH:5]=[CH:4][C:3]([NH:6][C:7]([C:9]2[CH:10]=[C:11]([NH:15][C:16]([N:18]3[CH2:27][C:26]4[CH:25]=[N:24][C:23]5[N:28](CC6C=CC(OC)=CC=6)[N:29]=[CH:30][C:22]=5[C:21]=4[CH2:20][CH2:19]3)=[O:17])[CH:12]=[CH:13][CH:14]=2)=[O:8])=[N:2]1.FC(F)(F)C(O)=O>C1(C)C=CC=CC=1>[O:1]1[CH:5]=[CH:4][C:3]([NH:6][C:7]([C:9]2[CH:10]=[C:11]([NH:15][C:16]([N:18]3[CH2:27][C:26]4[CH:25]=[N:24][C:23]5[NH:28][N:29]=[CH:30][C:22]=5[C:21]=4[CH2:20][CH2:19]3)=[O:17])[CH:12]=[CH:13][CH:14]=2)=[O:8])=[N:2]1Step 2 To the crude N-(3-(isoxazol-3-ylcarbamoyl)phenyl)-3-(4-methoxybenzyl)-8,9-dihydro-3H-pyrazolo[3,4-c][2,7]naphthyridine-7(6H)-carboxamide obtained above was added trifluoroacetic acid (1 mL). The reaction mixture was shaken at 65° C. for 16 hours. On completion of the reaction, toluene (1 mL) was added and solvent removed under reduced pressure. The crude product was purified reverse phase HPLC to give the desired product, N-(3-(isoxazol-3-ylcarbamoyl)phenyl)-8,9-dihydro-3H-pyrazolo[3,4-c][2,7]naphthyridine-7(6H)-carboxamide. LCMS [M+H]: 404.
読み込み中…